These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 26041408)

  • 21. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
    Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
    Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
    Devineni D; Polidori D; Curtin CR; Murphy J; Wang SS; Stieltjes H; Wajs E
    Int J Clin Pharmacol Ther; 2015 Jun; 53(6):438-46. PubMed ID: 25907176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
    Devineni D; Manitpisitkul P; Murphy J; Skee D; Wajs E; Mamidi RN; Tian H; Vandebosch A; Wang SS; Verhaeghe T; Stieltjes H; Usiskin K
    Clin Pharmacol Drug Dev; 2015; 4(3):226-36. PubMed ID: 27140803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
    Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
    Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
    Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K
    Adv Ther; 2017 Feb; 34(2):436-451. PubMed ID: 27981497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.
    Fediuk DJ; Nucci G; Dawra VK; Cutler DL; Amin NB; Terra SG; Boyd RA; Krishna R; Sahasrabudhe V
    Clin Pharmacokinet; 2020 Aug; 59(8):949-965. PubMed ID: 32337660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Scheen AJ
    Clin Pharmacokinet; 2014 Mar; 53(3):213-225. PubMed ID: 24430725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
    Brunton S; Reid TS
    Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Nicolle LE; Capuano G; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
    Sha S; Polidori D; Farrell K; Ghosh A; Natarajan J; Vaccaro N; Pinheiro J; Rothenberg P; Plum-Mörschel L
    Diabetes Obes Metab; 2015 Feb; 17(2):188-97. PubMed ID: 25421015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.
    Scheen AJ
    Clin Pharmacokinet; 2014 Apr; 53(4):295-304. PubMed ID: 24420910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
    Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canagliflozin use in patients with renal impairment-Utility of quantitative clinical pharmacology analyses in dose optimization.
    Khurana M; Vaidyanathan J; Marathe A; Mehrotra N; Sahajwalla CG; Zineh I; Jain L
    J Clin Pharmacol; 2015 Jun; 55(6):647-56. PubMed ID: 25612234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.
    Chen X; Hu P; Vaccaro N; Polidori D; Curtin CR; Stieltjes H; Sha S; Weiner S; Devineni D
    Clin Ther; 2015 Jul; 37(7):1483-1492.e1. PubMed ID: 26048186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
    Ohgaki R; Wei L; Yamada K; Hara T; Kuriyama C; Okuda S; Ueta K; Shiotani M; Nagamori S; Kanai Y
    J Pharmacol Exp Ther; 2016 Jul; 358(1):94-102. PubMed ID: 27189972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol.
    Fortuna D; McCloskey LJ; Stickle DF
    Clin Chim Acta; 2016 Jan; 452():138-41. PubMed ID: 26569347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
    Stein P; Berg JK; Morrow L; Polidori D; Artis E; Rusch S; Vaccaro N; Devineni D
    Metabolism; 2014 Oct; 63(10):1296-303. PubMed ID: 25110280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.
    Plosker GL
    Drugs; 2014 May; 74(7):807-24. PubMed ID: 24831734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
    Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
    J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.